ARTICLE | Company News
GammaCan International, Life Therapeutics deal
August 28, 2006 7:00 AM UTC
The companies will jointly develop GCAN's VitiGam second-generation intravenous immunoglobulin (IgG)-based immunotherapy, which is in preclinical testing to treat cancer. LEF will supply plasma, and ...